German scientists have developed a Covid-19 vaccine that can be inhaled instead of injected. The vaccine is designed to deliver the active ingredient directly to the lungs, where the virus causes the most damage. The vaccine is currently undergoing clinical trials to test its effectiveness and safety. The study is looking for healthy volunteers between the ages of 18 and 60 who have already received two doses of the Covid-19 vaccine.
The vaccine was developed by researchers at the Medical University of Hanover and the Fraunhofer Institute for Toxicology and Experimental Medicine. The vaccine is based on a vector vaccine that uses genetically modified pox viruses to trigger an immune response. The vaccine is delivered using a nebulizer that creates fine aerosols containing the active ingredients. The hope is that the vaccine will provide increased protection against the virus by triggering an immune response in the lungs, where the virus causes the most damage.
The clinical trial is being conducted by the Early Clinical Trial Unit (ECTU) and is looking for volunteers who have already received two doses of the Covid-19 vaccine. The study will test whether the vaccine can trigger the production of antibodies against the virus and whether it is safe. Volunteers will receive a thorough medical examination and will be compensated up to €1,500 for their participation. The vaccine has already been tested successfully on hamsters, and the researchers hope that it will provide a more effective form of protection against the virus than traditional vaccines.
